NCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
Clinical Trials
28 trialsNCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT05552807 2022-09-23
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1 Unknown
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT03057366 2019-11-18
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01868022 2019-08-19
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
Phase 1 Completed
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01911325 2018-08-14
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Novartis
Phase 1 Terminated
NCT00201812 2017-12-06
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01837667 2017-01-24
Phase I Study of LB-100 With Docetaxel in Solid Tumors
Lixte Biotechnology Holdings, Inc.
Phase 1 Completed
NCT00487786 2016-01-18
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
Achieve Life Sciences
Phase 1 Completed
NCT00798252 2015-07-07
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
Phase 1 Completed
NCT02171676 2014-06-24
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171741 2014-06-24
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT00183742 2014-05-22
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
University of Southern California
Phase 1 Completed
NCT00399087 2014-02-13
Phase I Trial of Docetaxel With Perifosine
AEterna Zentaris
Phase 1 Completed
NCT00545246 2013-10-16
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
Sanofi
Phase 1 Completed
NCT01204996 2012-05-30
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Centocor, Inc.
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00125411 2012-03-26
Study of Satraplatin (JM-216) in Combination With Docetaxel
Agennix
Phase 1 Terminated
NCT01148615 2012-01-13
A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
Sanofi
Phase 1 Completed
NCT00390676 2010-12-28
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
Adherex Technologies, Inc.
Phase 1 Completed
NCT00193570 2009-01-23
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed